Pharmacotherapy for bipolar disorder in adults with high-functioning autism. (13th October 2022)

• Record Type: Journal Article
• Authors: Amadori, Salvatore; Barbuti, Margherita; Perugi, Giulio
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 15(2022)
• Page Start: 1753
• Page End: 1760
• Publication Date: 2022-10-13
• Subjects: Autism spectrum disorder -- high-functioning autism -- bipolar disorder -- mood stabilizers; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2138332
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: The association between high-functioning autism (HFA) and bipolar disorder (BD) in adult subjects has been confirmed by a growing number of studies. However, identifying and treating BD in this population is a clinical challenge and requires careful assessment and adequate knowledge of both disorders. Areas covered: This review aims to provide a clinical presentation of mood episodes in HFA individuals, and an update on the pharmacotherapy of BD in these individuals, sharing with the reader expert opinion on the current state of the art and future perspectives. Expert opinion: BD has an atypical clinical presentation in HFA subjects with the possibility of diagnostic and therapeutic mistakes. Despite the absence of controlled studies, the available evidence indicates mood stabilizers, especially lithium, as the first treatment option. HFA subjects are particularly vulnerable to pharmacological side effects, such as extrapyramidal and catatonic symptoms with antipsychotics, or activation syndrome with antidepressants. Accordingly, initial titration of these drugs should be slow and their use should be limited in time. Among antipsychotics, dopamine receptor antagonists with combined serotonergic activity are preferable. Further research is needed to improve the diagnostic process and to delineate the effectiveness of different drugs for BD in HFA subjects.